高风险早期卵巢癌化疗前血清CA-125的临床与预后意义:NRG/GOG辅助研究
本研究基于GOG 157随机试验中350例高风险早期上皮性卵巢癌患者,分析化疗前、中、后CA-125变化与生存的关系。结果显示化疗前CA-125正常及首周期化疗后CA-125正常化与更好的无复发生存和总生存相关。
要点
- 化疗前CA-125正常及首周期后正常化与更好生存相关。
- 首周期后CA-125未正常化者5年RFS和OS较差。
- CA-125下降百分比及绝对值谷值不预测结局。
核心结论
- 化疗前CA-125正常及首周期化疗后CA-125正常化与高风险早期上皮性卵巢癌患者更好的生存相关。
研究设计与样本
- 研究纳入GOG 157 III期随机试验中350例高风险早期上皮性卵巢癌患者,均接受初始手术后紫杉醇/卡铂化疗3或6个周期。
- 采用Kaplan-Meier法和Cox比例风险模型评估无复发生存(RFS)和总生存(OS)。
主要发现
- 350例患者化疗前CA-125中位值为65(IQR:31-129)。
- 白人患者中71%化疗前CA-125升高,非白人患者中47%升高(p=0.006)。
- 化疗前CA-125升高者中,首周期化疗后74%正常化。
- 首周期后CA-125正常化者较未正常化者5年RFS为81% vs 65%(p=0.003),OS为87% vs 75%(p=0.009)。
- 首周期后CA-125变化模式正常至正常 vs 升高至正常 vs 升高至升高对应RFS为87% vs 80% vs 68%(p=0.013),OS为92% vs 88% vs 77%(p=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the clinical and prognostic significance of CA-125 trends prior to, during, and after chemotherapy in high-risk early-stage epithelial ovarian cancer patients. METHODS: All patients were enrolled in a phase III randomized trial (GOG 157) following upfront surgery for grade 3 stage IA/IB, stage IC, or stage II disease, and had been treated with either three or six cycles of carboplatin/paclitaxel. Kaplan-Meier method and Cox proportional hazards model were used to evaluate recurrence-free survival (RFS) and overall survival (OS). RESULTS: Of 350 patients, the median pre-chemotherapy CA-125 was 65 (IQR: 31-129). 71% of Whites had an elevated CA-125 compared to 47% of non-Whites (p = 0.006). Following the first cycle of chemotherapy, 74% of those with elevated CA-125 had normalization. Those who had normalization of CA-125 after 1 cycle had significantly better 5-year RFS (81% vs. 65%, p = 0.003) and OS (87% vs. 75%, p = 0.009) compared to those who did not normalize (defined as ≤35 U/mL). The pattern of CA-125 change following chemotherapy cycle 1, from normal to normal vs. elevated to normal vs. elevated to elevated had corresponding RFS of 87% vs. 80% vs. 68% (p = 0.013), and OS of 92% vs. 88% vs. 77% (p = 0.009). However, the percent decline (p = 0.993) and absolute nadir normal value of CA-125 (0-10 vs. 11-35 U/mL) were not predictive of outcome (p = 0.4). CONCLUSIONS: Normal baseline CA125 and normalization of this biomarker after the first cycle of chemotherapy were associated with better survival in high-risk early-stage epithelial ovarian cancer patients.
引用
- Chan JK, Tian C, Kesterson JP, et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. Gynecol Oncol. 2022. PMID: 36244828. doi:10.1016/j.ygyno.2022.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。